Skip to main content

Table 2 Offer of any HCV testing services (offer of either on-site or off-site HCV testing) in Opioid Treatment Programs

From: Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services

 

(Any HCV testing vs. No testing)

OR (95% CI)

Predictor variables

 

 Director race/ethnicity

 

  African-American

1.98 (0.65, 5.96)

  Other race/ethnicity

0.42 (0.13, 1.27)

  White

1†

 Director age

1.01 (0.97, 1.03)

 Director gender

 

  Female

0.67 (0.37 1.18)

  Male

1†

 Director education

 

  Post-graduate training or more

0.57 (0.28, 1.16)

  College or less

1†

 Director sources of information

1.50 (0.87, 2.58)

 Director support of preventive services

1.39 (1.02, 1.90)*

Control variables

 

  Patient characteristics

 

  Percent African-American patients

0.99 (0.97, 1.00)^

  Percent Hispanic / Latino patients

1.03 (1.00, 1.04)*

  Percent female patients

0.99 (0.96, 1.00)

  Percent persons who inject drugs

1.00 (0.99, 1.01)

  Program characteristics

 

  CARF accreditation

 

   Yes

1.53 (0.75, 3.10)

   No

1†

  Ownership

 

   Public

1.10 (0.43, 2.76)

   Private for-profit

1.12 (0.53, 2.34)

   Private not-for-profit

1†

  Method of treatment

 

   Both (Meth + Bup)

6.41 (1.69, 24.1)*

   Buprenorphine only (Bup)

1.32 (0.58, 2.99)

   Methadone only (Meth)

1†

  Staff - patient ratio

1.34 (0.91, 1.94)

  Prior authorization

1.00 (0.98, 1.00)

  Revenue from federal sources

 

   At least 1%

1.40 (0.71, 2.73)

   None

1†

  Revenue from private insurance

 

   At least 1%

0.67 (0.33, 1.33)

   None

1†

  Year

 

   2005

0.30 (0.15, 0.58)***

   2011

1†

  1. A total of 383 OTPs were included in the analysis
  2. Ninety-five percent confidence intervals estimated with robust standard errors
  3. † Reference category; OR, Odds ratio; CI, Confidence interval
  4. ^p< 0.10. *p < 0.05. **p < 0.01.